#xbb15 — Public Fediverse posts

#Neutralization and #Stability of #JN1-derived #LB1, #KP23, #KP3 and #KP311 #Subvariants http://biorxiv.org/cgi/content/short/2024.09.04.611219v1?rss=1

We report on the neutralizing #antibody (nAb) #escape, infectivity, #fusion, and stability of these subvariants-LB.1, KP.2.3, KP.3, and KP.3.1.1. Our findings demonstrate that all of these subvariants are highly evasive of nAbs elicited by bivalent #mRNA #vaccine, the #XBB15 monovalent mumps virus-based vaccine, or from infections during the BA.2.86/JN.1 wave.

#Neutralization and #Stability of #JN1-derived #LB1, #KP23, #KP3 and #KP311 #Subvariants http://biorxiv.org/cgi/content/short/2024.09.04.611219v1?rss=1

We report on the neutralizing #antibody (nAb) #escape, infectivity, #fusion, and stability of these subvariants-LB.1, KP.2.3, KP.3, and KP.3.1.1. Our findings demonstrate that all of these subvariants are highly evasive of nAbs elicited by bivalent #mRNA #vaccine, the #XBB15 monovalent mumps virus-based vaccine, or from infections during the BA.2.86/JN.1 wave.

#Neutralization and #Stability of #JN1-derived #LB1, #KP23, #KP3 and #KP311 #Subvariants http://biorxiv.org/cgi/content/short/2024.09.04.611219v1?rss=1

We report on the neutralizing #antibody (nAb) #escape, infectivity, #fusion, and stability of these subvariants-LB.1, KP.2.3, KP.3, and KP.3.1.1. Our findings demonstrate that all of these subvariants are highly evasive of nAbs elicited by bivalent #mRNA #vaccine, the #XBB15 monovalent mumps virus-based vaccine, or from infections during the BA.2.86/JN.1 wave.

#Neutralization and #Stability of #JN1-derived #LB1, #KP23, #KP3 and #KP311 #Subvariants http://biorxiv.org/cgi/content/short/2024.09.04.611219v1?rss=1

We report on the neutralizing #antibody (nAb) #escape, infectivity, #fusion, and stability of these subvariants-LB.1, KP.2.3, KP.3, and KP.3.1.1. Our findings demonstrate that all of these subvariants are highly evasive of nAbs elicited by bivalent #mRNA #vaccine, the #XBB15 monovalent mumps virus-based vaccine, or from infections during the BA.2.86/JN.1 wave.

#Neutralization and #Stability of #JN1-derived #LB1, #KP23, #KP3 and #KP311 #Subvariants http://biorxiv.org/cgi/content/short/2024.09.04.611219v1?rss=1

We report on the neutralizing #antibody (nAb) #escape, infectivity, #fusion, and stability of these subvariants-LB.1, KP.2.3, KP.3, and KP.3.1.1. Our findings demonstrate that all of these subvariants are highly evasive of nAbs elicited by bivalent #mRNA #vaccine, the #XBB15 monovalent mumps virus-based vaccine, or from infections during the BA.2.86/JN.1 wave.

Immunogenicity and #efficacy of #XBB15 rS #vaccine against the #EG51 #variant of #SARS-CoV-2 in Syrian #hamsters, J Virol.: https://journals.asm.org/doi/full/10.1128/jvi.00528-24?af=R

Thus, based on these study results, the protein-based XBB.1.5 vaccine is immunogenic and increased the breadth of protection against the Omicron EG.5.1 variant in the Syrian hamster model.

“According to the federal government, 23 per cent of #BritishColumbians have been vaccinated with the #XBB15 vaccine, which was first distributed in the fall of 2023 and offered again through this spring’s 2024 campaign.

This represents one of the highest vaccination rates in the country, where the national average is 18 per cent vaccinated — but it’s still less than one-third of #BC.’s population, and that #COVID strain is no longer dominant,”

“According to the federal government, 23 per cent of #BritishColumbians have been vaccinated with the #XBB15 vaccine, which was first distributed in the fall of 2023 and offered again through this spring’s 2024 campaign.

This represents one of the highest vaccination rates in the country, where the national average is 18 per cent vaccinated — but it’s still less than one-third of #BC.’s population, and that #COVID strain is no longer dominant,”

“According to the federal government, 23 per cent of #BritishColumbians have been vaccinated with the #XBB15 vaccine, which was first distributed in the fall of 2023 and offered again through this spring’s 2024 campaign.

This represents one of the highest vaccination rates in the country, where the national average is 18 per cent vaccinated — but it’s still less than one-third of #BC.’s population, and that #COVID strain is no longer dominant,”

“According to the federal government, 23 per cent of #BritishColumbians have been vaccinated with the #XBB15 vaccine, which was first distributed in the fall of 2023 and offered again through this spring’s 2024 campaign.

This represents one of the highest vaccination rates in the country, where the national average is 18 per cent vaccinated — but it’s still less than one-third of #BC.’s population, and that #COVID strain is no longer dominant,”

“According to the federal government, 23 per cent of #BritishColumbians have been vaccinated with the #XBB15 vaccine, which was first distributed in the fall of 2023 and offered again through this spring’s 2024 campaign.

This represents one of the highest vaccination rates in the country, where the national average is 18 per cent vaccinated — but it’s still less than one-third of #BC.’s population, and that #COVID strain is no longer dominant,”

#SARS-CoV-2 #BA4/5 #infection triggers more cross-reactive FcγRIIIa signaling and #neutralization than #BA1, in the context of #hybrid #immunity, J Virol.: https://journals.asm.org/doi/full/10.1128/jvi.00678-24?af=R

Although this is consistent with enhanced neutralization and FcγRIIIa signaling breadth of BA.4/5 vaccine boosters, the reduced activity against #XBB15 supports the need to update vaccines with XBB sublineage immunogens to provide adequate coverage of these highly antibody evasive variants.

#SARS-CoV-2 #BA4/5 #infection triggers more cross-reactive FcγRIIIa signaling and #neutralization than #BA1, in the context of #hybrid #immunity, J Virol.: https://journals.asm.org/doi/full/10.1128/jvi.00678-24?af=R

Although this is consistent with enhanced neutralization and FcγRIIIa signaling breadth of BA.4/5 vaccine boosters, the reduced activity against #XBB15 supports the need to update vaccines with XBB sublineage immunogens to provide adequate coverage of these highly antibody evasive variants.

#SARS-CoV-2 #BA4/5 #infection triggers more cross-reactive FcγRIIIa signaling and #neutralization than #BA1, in the context of #hybrid #immunity, J Virol.: https://journals.asm.org/doi/full/10.1128/jvi.00678-24?af=R

Although this is consistent with enhanced neutralization and FcγRIIIa signaling breadth of BA.4/5 vaccine boosters, the reduced activity against #XBB15 supports the need to update vaccines with XBB sublineage immunogens to provide adequate coverage of these highly antibody evasive variants.

#SARS-CoV-2 #BA4/5 #infection triggers more cross-reactive FcγRIIIa signaling and #neutralization than #BA1, in the context of #hybrid #immunity, J Virol.: https://journals.asm.org/doi/full/10.1128/jvi.00678-24?af=R

Although this is consistent with enhanced neutralization and FcγRIIIa signaling breadth of BA.4/5 vaccine boosters, the reduced activity against #XBB15 supports the need to update vaccines with XBB sublineage immunogens to provide adequate coverage of these highly antibody evasive variants.

#SARS-CoV-2 #BA4/5 #infection triggers more cross-reactive FcγRIIIa signaling and #neutralization than #BA1, in the context of #hybrid #immunity, J Virol.: https://journals.asm.org/doi/full/10.1128/jvi.00678-24?af=R

Although this is consistent with enhanced neutralization and FcγRIIIa signaling breadth of BA.4/5 vaccine boosters, the reduced activity against #XBB15 supports the need to update vaccines with XBB sublineage immunogens to provide adequate coverage of these highly antibody evasive variants.

#Durability of #XBB15 #Vaccines against #Omicron #Subvariants, N Engl J Med.: https://www.nejm.org/doi/full/10.1056/NEJMc2402779?query=TOC&cid=DM2342986_Non_Subscriber&bid=-1971795569

Overall, the XBB.1.5 vaccines were effective against omicron subvariants, although less so against #JN1. Effectiveness was greater against #hospitalization and #death than against infection, and it waned moderately from its peak over time. The ramping and waning patterns were broadly similar to those of the bivalent boosters against BQ.1–BQ.1.1 and XBB–XBB.1.5.3

Characteristics of #JN1-derived #SarsCoV2 #subvariants #SLip, #FLiRT, and #KP2 in neutralization #escape, #infectivity and membrane #fusion http://biorxiv.org/cgi/content/short/2024.05.20.595020v1?rss=1

Interestingly, #antibodies in #XBB15 monovalent vaccinated hamster sera robustly neutralized FLiRT and KP.2 but had reduced efficiency for SLip.

Characteristics of #JN1-derived #SarsCoV2 #subvariants #SLip, #FLiRT, and #KP2 in neutralization #escape, #infectivity and membrane #fusion http://biorxiv.org/cgi/content/short/2024.05.20.595020v1?rss=1

Interestingly, #antibodies in #XBB15 monovalent vaccinated hamster sera robustly neutralized FLiRT and KP.2 but had reduced efficiency for SLip.

Characteristics of #JN1-derived #SarsCoV2 #subvariants #SLip, #FLiRT, and #KP2 in neutralization #escape, #infectivity and membrane #fusion http://biorxiv.org/cgi/content/short/2024.05.20.595020v1?rss=1

Interestingly, #antibodies in #XBB15 monovalent vaccinated hamster sera robustly neutralized FLiRT and KP.2 but had reduced efficiency for SLip.

Characteristics of #JN1-derived #SarsCoV2 #subvariants #SLip, #FLiRT, and #KP2 in neutralization #escape, #infectivity and membrane #fusion http://biorxiv.org/cgi/content/short/2024.05.20.595020v1?rss=1

Interestingly, #antibodies in #XBB15 monovalent vaccinated hamster sera robustly neutralized FLiRT and KP.2 but had reduced efficiency for SLip.

Characteristics of #JN1-derived #SarsCoV2 #subvariants #SLip, #FLiRT, and #KP2 in neutralization #escape, #infectivity and membrane #fusion http://biorxiv.org/cgi/content/short/2024.05.20.595020v1?rss=1

Interestingly, #antibodies in #XBB15 monovalent vaccinated hamster sera robustly neutralized FLiRT and KP.2 but had reduced efficiency for SLip.

#Virological characteristics of the #SarsCoV2 #KP2 #variant http://biorxiv.org/cgi/content/short/2024.04.24.590786v1?rss=1

Particularly, KP.2 shows the most significant #resistance to the #sera of monovalent #XBB15 #vaccinee without #infection (3.1-fold) as well as those who with infection (1.8-fold). Altogether, these results suggest that the increased immune resistance ability of KP.2 partially contributes to the higher Re more than previous variants including JN.1.

Evaluating #Humoral #Immunity Elicited by #XBB15 Monovalent #COVID19 #Vaccine, Emerg Infect Dis.: https://wwwnc.cdc.gov/eid/article/30/6/24-0051_article

We report boosting of #IgG (2.1×), #IgA (1.5×), and total IgG/A/M (1.7×) targeting the #spike receptor-binding domain and neutralizing titers against WA1 (2.2×), XBB.1.5 (7.4×), #EG51 (10.5×), and #JN1 (4.7×) variants.

[Correspondence] #Effectiveness of #XBB15 #vaccines and #antiviral drugs against severe #outcomes of #omicron infection in the #USA https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00150-6/fulltext?rss=yes

#XBB15 monovalent #mRNA #vaccine #booster elicits robust neutralizing #antibodies against #XBB subvariants and #JN1, Cell Host Microbe: https://doi.org/10.1016/j.chom.2024.01.014

• An XBB.1.5 booster markedly enhanced neutralization of SARS-CoV-2, including JN.1
• An XBB.1.5 booster induced similar antibody titers to XBB infection
• Omicron infection followed by XBB.1.5 booster yielded the highest antibody titers
• Our findings supported recommendations for broad use of the updated XBB.1.5 booster

🇳🇿New Zealand: New COVID vaccine now available in NZ - here’s what you need to know | nzherald.co.nz

#COVID19NZ #COVIDvaccine #XBB15 @auscovid19

Source: https://www.nzherald.co.nz/nz/nzs-new-covid-19-vaccine-rolls-out-today-heres-what-you-need-to-know/4KUSJQXXB5DZHAICME5O4DHJ44/

Altered #receptor #binding, #antibody #evasion and retention of T cell recognition by the #SARS-CoV-2 #XBB15 #spike protein, Nat Commun.: https://www.nature.com/articles/s41467-024-46104-2

-- while the XBB.1.5 #variant has retained efficient human receptor binding and gained #antigenic alterations, it remains susceptible to recognition by T cells induced via vaccination and previous infection.

{Research Letter} Adverse #Events After #XBB15 -Containing #COVID19 #mRNA #Vaccines, JAMA: https://jamanetwork.com/journals/jama/fullarticle/2815787?guestAccessKey=0726a751-3d5a-4fe9-8684-8def4f77331a&utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jama&utm_content=olf&utm_term=022624&adv=000003602429

-- In a nationwide cohort of more than 1 million adults aged 65 years and older, no increased risk of 28 adverse events was observed following vaccination with a monovalent XBB.1.5-containing vaccine.

#Virological characteristics of the #SARS-CoV-2 #Omicron #XBB15 #variant, Nat Commun.: https://www.nature.com/articles/s41467-024-45274-3

-- We provide intrinsic pathogenicity of XBB.1 & XBB.1.5 in hamsters. ...we find that #ORF8 nonsense mutation of XBB.1.5 resulted in impairment of #MHC suppression. In vivo experiments using recombinant viruses reveal that XBB.1.5 mutations are involved with reduced virulence of XBB.1.5... our study identifies 2 viral functions defined difference between XBB.1 & XBB.1.5.

#Virological characteristics of the #SARS-CoV-2 #Omicron #XBB15 #variant, Nat Commun.: https://www.nature.com/articles/s41467-024-45274-3

-- We provide intrinsic pathogenicity of XBB.1 & XBB.1.5 in hamsters. ...we find that #ORF8 nonsense mutation of XBB.1.5 resulted in impairment of #MHC suppression. In vivo experiments using recombinant viruses reveal that XBB.1.5 mutations are involved with reduced virulence of XBB.1.5... our study identifies 2 viral functions defined difference between XBB.1 & XBB.1.5.

#Virological characteristics of the #SARS-CoV-2 #Omicron #XBB15 #variant, Nat Commun.: https://www.nature.com/articles/s41467-024-45274-3

-- We provide intrinsic pathogenicity of XBB.1 & XBB.1.5 in hamsters. ...we find that #ORF8 nonsense mutation of XBB.1.5 resulted in impairment of #MHC suppression. In vivo experiments using recombinant viruses reveal that XBB.1.5 mutations are involved with reduced virulence of XBB.1.5... our study identifies 2 viral functions defined difference between XBB.1 & XBB.1.5.

#Virological characteristics of the #SARS-CoV-2 #Omicron #XBB15 #variant, Nat Commun.: https://www.nature.com/articles/s41467-024-45274-3

-- We provide intrinsic pathogenicity of XBB.1 & XBB.1.5 in hamsters. ...we find that #ORF8 nonsense mutation of XBB.1.5 resulted in impairment of #MHC suppression. In vivo experiments using recombinant viruses reveal that XBB.1.5 mutations are involved with reduced virulence of XBB.1.5... our study identifies 2 viral functions defined difference between XBB.1 & XBB.1.5.

#Virological characteristics of the #SARS-CoV-2 #Omicron #XBB15 #variant, Nat Commun.: https://www.nature.com/articles/s41467-024-45274-3

-- We provide intrinsic pathogenicity of XBB.1 & XBB.1.5 in hamsters. ...we find that #ORF8 nonsense mutation of XBB.1.5 resulted in impairment of #MHC suppression. In vivo experiments using recombinant viruses reveal that XBB.1.5 mutations are involved with reduced virulence of XBB.1.5... our study identifies 2 viral functions defined difference between XBB.1 & XBB.1.5.

Link-Gelles R, Ciesla AA, Mak J, et al. Early #Estimates of Updated 2023–2024 (Monovalent #XBB15) #COVID19 #Vaccine #Effectiveness Against Symptomatic #SARS-CoV-2 #Infection Attributable to Co-Circulating #Omicron Variants Among Immunocompetent Adults — Increasing Community Access to Testing Program, #USA, Sept 2023–Jan 2024. MMWR Morb Mortal Wkly Rep 2024;73:77–83. DOI: http://dx.doi.org/10.15585/mmwr.mm7304a2

-- En relación con la #Covid19, explicó en un artículo publicado en la página web del Minsap, que en los últimos dos meses del 2023 y los días transcurridos del 2024 se ha identificado principalmente la presencia de tres #subvariantes de #Ómicron: #XBB15, #XBB19 y #XBB116, clasificadas por la OMS como de interés o bajo vigilancia.

-- En relación con la #Covid19, explicó en un artículo publicado en la página web del Minsap, que en los últimos dos meses del 2023 y los días transcurridos del 2024 se ha identificado principalmente la presencia de tres #subvariantes de #Ómicron: #XBB15, #XBB19 y #XBB116, clasificadas por la OMS como de interés o bajo vigilancia.

-- En relación con la #Covid19, explicó en un artículo publicado en la página web del Minsap, que en los últimos dos meses del 2023 y los días transcurridos del 2024 se ha identificado principalmente la presencia de tres #subvariantes de #Ómicron: #XBB15, #XBB19 y #XBB116, clasificadas por la OMS como de interés o bajo vigilancia.

-- En relación con la #Covid19, explicó en un artículo publicado en la página web del Minsap, que en los últimos dos meses del 2023 y los días transcurridos del 2024 se ha identificado principalmente la presencia de tres #subvariantes de #Ómicron: #XBB15, #XBB19 y #XBB116, clasificadas por la OMS como de interés o bajo vigilancia.

-- En relación con la #Covid19, explicó en un artículo publicado en la página web del Minsap, que en los últimos dos meses del 2023 y los días transcurridos del 2024 se ha identificado principalmente la presencia de tres #subvariantes de #Ómicron: #XBB15, #XBB19 y #XBB116, clasificadas por la OMS como de interés o bajo vigilancia.

-- The significant increase in anti-S #IgG, expansion of diverse S-specific MBC populations, and enhanced neutralising responses position the updated #XBB15 #vaccine as a critical #tool for enhancing #protection in vulnerable populations against evolving #SARS-CoV-2 #variants.

[Correspondence] Immune responses following #BNT162b2 #XBB15 #vaccination in patients on #haemodialysis in #Germany https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00783-1/fulltext?rss=yes

-- These observations suggest that a single dose of #XBB15 monovalent #vaccine potentially induces antiviral humoral #immunity against XBB subvariants as well as #BA286 without previous infection.

[Correspondence] Antiviral humoral #immunity against #SARS-CoV-2 #omicron #subvariants induced by #XBB15 monovalent #vaccine in #infection-naive and XBB-infected individuals https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00784-3/fulltext?rss=yes

[Correspondence] Short-term #effectiveness of the #XBB15 updated #COVID19 #vaccine against #hospitalisation in #Denmark: a national cohort study https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00746-6/fulltext?rss=yes

-- In summary, early results from cohort analyses with natl health registry data in indicate a high level of protection from XBB.1.5 vaccine, at least in short term; vaccination was associated with a 76·1% reduced risk of COVID-19 hospitalisation in a population vaccinated with a booster dose the previous season.

[Correspondence] #Humoral immune #responses to the monovalent #XBB15-adapted BNT162b2 #mRNA #booster in #Sweden https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00779-X/fulltext?rss=yes

-- In summary, monovalent XBB.1.5-adapted booster vaccination substantially enhanced both binding and neutralising antibody responses against a spectrum of variants in an older population with four or more previous vaccine doses.

Deep #mutational #scans of #XBB15 and #BQ11 reveal ongoing epistatic #drift during #SARS-CoV-2 #evolution https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1011901

Deep #mutational #scans of #XBB15 and #BQ11 reveal ongoing epistatic #drift during #SARS-CoV-2 #evolution https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1011901

Deep #mutational #scans of #XBB15 and #BQ11 reveal ongoing epistatic #drift during #SARS-CoV-2 #evolution https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1011901

Deep #mutational #scans of #XBB15 and #BQ11 reveal ongoing epistatic #drift during #SARS-CoV-2 #evolution https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1011901